Autologous Adrenal Medullary Transplant in Progressive Supranuclear Palsy
Neurol 39:1066-1068, Koller,W.C.,et al, 1989
MR Imaging in Progressive Suupranuclear Palsy and Shy-Drager Syndrome
J Comput Assist Tomogr 13:555-560, Savoiardo,M.,et al, 1989
Diltiazem-Induced Parkinsonism
Am J Med 87:95-96, Dick,R.S.&Barold,S.S., 1989
Risk Factors for Recurrent Nonsyncopal Falls, A Prospective Study
JAMA 261:2663-2668, Nevitt,M.C.,et al, 1989
Pergolide and Selegiline for Parkinson's Disease
The Medical Letter, 31:81-841989., , 1989
Continuous Levodopa Infusions to Treat Complex Dystonia in Parkinson's Disease
Neurol 39:888-891, Sage,J.I.,et al, 1989
Dopa Responsive Dystonia:A Treatable Condition Misdiagnosed as Cerebral Palsy
BMJ 298:1019-1020, Boyd,K.&Patterson,V., 1989
Cognitive Impairments Associated with Early Parkinson's Disease
Neurol 39:557-561, Levin,B.E.,et al, 1989
Clinical and Pathological Aspects of Parkinsonism in Alzheimer's Disease, A Role for Extranigral Factors?
Arch Neurol 46:651-657, Morris,J.C.,et al, 1989
Neuropathological Distinction Between Parkinson's Dementia and Parkinson's Plus Alzheimer's Disease
Ann Neurol 26:309-320, delaMonte,S.M.,et al, 1989
Environmental Factors and Parkinson's Disease:A Case-Control Study in China
Neurol 39:660-664, Tanner,C.M.,et al, 1989
Long-Term Efficacy and Safety of Deprenyl (Selegiline) in Advanced Parkinson's Disease
Neurol 39:1109-1111, Golbe,L.I.,et al, 1989
The Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's Disease
Science 245:519-522, Tetrud,J.W.&Langston,W., 1989
Agonist Substitution in Advanced Parkinson's Disease
Neurol 39:1121-1122, Goetz,C.G.,et al, 1989
Physiology & Pharmacology of Dopamine D2-Receptors:Their Implications in Dopamine-Substitute Therapy for Park
Neurol 39:1106-1108, Mercuri,N.B.,et al, 1989
Human Fetal Dopamine Neurons Grafted Into the Striatum in Two Patients with Severe Parkinson's 6-Mo Follow-up
Arch Neurol 46:615-631, Lindvall,O.,et al, 1989
The Ethical Use of Human Fetal Tissue in Medicine
NEJM 320:1093-1096, Greely,H.T.,et al, 1989
The Politics of Transplantation of Human Fetal Tissue
NEJM 320:1079-1082, Annas,G.J.&Elias,S., 1989
Postmortem Analysis of Adrenal-Medulla-to-Caudate Autograft in a Patient with Parkinson's Disease
Ann Neurol 25:607-614, Hurtig,H.,et al, 1989
Adrenal Medullary Transplantation to the Caudate Nucleus in Parkinson's Disease, Initial Results in 18 Patients
Arch Neurol 46:487-491, Allen,G.S.,et al, 1989
Adrenal Medullary Autografts in Patients with Parkinson's Disease
NEJM 321:324-327, Tanner,C.M.,et al, 1989
Clinical, Biochem, & Neuropath of Transplantation of Adrenal Medulla to Caudate Nucleus for Parkinson's
Neurol 39:1227-1234, Jankovic,J.,et al, 1989
Amount and Distribution of Dietary Protein Affects Clinical Response to Levodopa in Parkinson's Disease
Neurol 39:552-556, Carter,J.H., 1989
Influence of Fluctuations of Plasma Large Neutral Amino Acids with Normal Diets on the Clinical Response to Levodopa
JNNP 52:481-487, Nutt,J.G.,et al, 1989
The Effect of Dietary Protein on the Efficacy of L-Dopa:A Double-Blind Study
Neurol 39:549-552, Tsui,J.K.,et al, 1989
Accuracy of Self-Reported Disability in Patients with Parkinsonism
Arch Neurol 46:955-959, Brown,R.G.,et al, 1989
Psychiatric Aspects of Parkinson's Disease, Dementia, Depression, and Rarely Psychosis
BMJ 299:3-4, Baldwin,R.C.&Byrne,E.J., 1989
Effect of Age at Onset on Progression and Mortality in Parkinson's Disease
Neurol 39:1187-1190, Diamond,S.G.,et al, 1989
Diffuse Lewy Body Disease:Clinical Features in 15 Cases
JNNP 52:709-717, Byrne,E.J., 1989
The Efficacy of (+) -4-Propyl-9-Hydroxynaphthoxazine as Adjunctive Therapy in Parkinson's Disease
JNNP 52:732-735, Weiner,W.J.,et al, 1989
Diffuse Lewy Body Disease and Progressive Dementia
Neurol 38:1520-1528, Burkhardt,C.R.,et al, 1988
Hand Contractures in Parkinson's Disease
JNNP 51:1221-1223, Kyriakides,T.&Hewer,R.L., 1988
PHNO[ (+) -4-Propyl-9-Hydroxynaphthoxazine]:A New and Effective Anti-Parkinson's Disease Agent
Neurol 38:1541-1545, Muenter,M.D.,et al, 1988
Risk Factors for Progression in Parkinson's Disease
Neurol 38:1841-1844, Goetz,C.G.,et al, 1988
Role of Subcutaneous Apomorphine in Parkinsonian Voiding Dysfunction
Lancet 2:1451-1453, Christmas,T.J.,et al, 1988
Dementia and Cognitive Impairment in Parkinson's Disease
JNNP 51:1498-1502, Girotti,F.,et al, 1988
Parkinsonism Death Rates by Race, Sex, and Geography
Neurol 38:1558-1561, Kurtzke,J.F.&Goldberg,I.D., 1988
Amitriptyline in the Treatment of Headache in Patients with Parkinson's Disease:Double-Blind Study
Neurol 38:1720-1721, Indaco,A.&Carrieri,P.B., 1988
Dystonic-Parkinsonian Syndrome after Cyanide Poisoning:Clinical and MRI Findings
JNNP 51:1345-1348, Carella,F.,et al, 1988
Parkinsonian Syndrome Caused by a Tumour of the Left Supplementary Motor Area
JNNP 51:730-731, Straube,A.&Sigel,K., 1988
A Comparison of Clinical and Pathological Features of Young-and Old-Onset Parkinson's Disease
Neurol 38:1402-1406, Gibb,W.R.G.&Lees,A.J., 1988
Parkinsonism, Tremor, and Depression Induced by Cinnarizine and Flunarizine
BMJ 297:722-723, Capella,D.,et al, 1988
Tetrabenazine Therapy of Dystonia, Chorea, Tics, & Other Dyskinesias
Neurol 38:391-394, Jankovic,J.&Orman,J., 1988
Drug-Induced Alzheimerism
Arch Neurol 45:356-357, Kurlan,R.&Como,P., 1988
International Symposium on Early Dopamine Agonist Therapy of Parkinson's Disease
Arch Neurol 45:204-208, Kurlan,R., 1988
Subcutaneous Apomorphine in Parkinsonian On-Off Oscillations
Lancet 1:403-406, Stibe,C.M.H.,et al, 1988
Dystonia in Parkinson's Disease:Clinical & Pharmacological Features
Ann Neurol 23:73-78, Poewe,W.H.,et al, 1988
An Estimate of the Prevalence of Dementia in Idiopathic Parkinson's Disease
Arch Neurol 45:260-262, Mayeux,R.,et al, 1988
A Double-Blind Trial of Clonazepam in the Treatment of Parkinsonian Dysarthria
Neurol 38:255-258, Biary,N.,et al, 1988
Transplantation of Fetal Substantia Nigra & Adrenal Medulla to the Caudate Nucleus in Two Patients with Parkinson's Disease
NEJM 318:51, Madrazo,I.,et al, 1988